S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Baker Bros Advisors/Q3 2023

Baker Bros Advisors

Period: Q3 2023 Β· Filed: 2023-11-14
View on SEC EDGAR β†—
AUM
$17.35B
Total portfolio value
Positions
101
Reported securities
Top Holding
SGEN
54.5% $9.45B
QoQ Changes
+8 / -8
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2023-11-14) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
SGENSeagen Inc.$9.45B54.48%β€”β€”
54.5%
ONCBeiGene, Ltd.$2.10B12.10%$178.50$297.65+66.8%
12.1%
INCYIncyte Corporation$2.09B12.05%$58.06$116.86+101.3%
12.1%
ACADACADIA Pharmaceuticals Inc.$893.3M5.15%$21.47$25.97+21.0%
5.2%
BMRNBioMarin Pharmaceutical Inc.$337.1M1.94%$87.08$58.99-32.3%
1.9%
MDGLMadrigal Pharmaceuticals, Inc.$225.7M1.30%$143.36$528.10+268.4%
1.3%
RYTMRhythm Pharmaceuticals, Inc.$153.7M0.89%$22.10$114.17+416.6%
0.9%
ROIVRoivant Sciences Ltd.$138.7M0.80%$10.52$35.13+233.9%
0.8%
IMCRImmunocore Holdings plc$130.8M0.75%$48.02$32.50-32.3%
0.8%
Invitae Corporation$130.4M0.75%β€”β€”
0.8%
AKROAkero Therapeutics, Inc.$119.8M0.69%β€”β€”
0.7%
ABCLAbCellera Biologics Inc.$95.5M0.55%$4.46$8.11+81.8%
0.6%
BCRXBioCryst Pharmaceuticals, Inc.$90.0M0.52%$6.77$9.84+45.4%
0.5%
REPLReplimune Group, Inc.$78.3M0.45%$15.79$11.58-26.7%
0.5%
TRDAEntrada Therapeutics, Inc.$76.9M0.44%$14.85$7.72-48.0%
0.4%
RVMDRevolution Medicines, Inc.$74.5M0.43%$26.17$189.24+623.1%
0.4%
ARGXargenx SE$74.3M0.43%$487.32$939.68+92.8%
0.4%
SWTXSpringWorks Therapeutics, Inc.$69.4M0.40%β€”β€”
0.4%
KYMRKymera Therapeutics, Inc.$66.0M0.38%$13.57$113.51+736.5%
0.4%
IMTXImmatics N.V.$65.3M0.38%$10.79$9.95-7.8%
0.4%
MRTXMirati Therapeutics, Inc.$61.4M0.35%β€”β€”
0.3%
KNSAKiniksa Pharmaceuticals, Ltd.$48.8M0.28%$16.90$64.53+281.8%
0.3%
RAREUltragenyx Pharmaceutical Inc.$48.7M0.28%$34.80$33.47-3.8%
0.3%
DNLIDenali Therapeutics Inc.$47.3M0.27%$19.79$25.83+30.5%
0.3%
PRLDPrelude Therapeutics Inc.$31.3M0.18%$2.77$4.91+77.3%
0.2%
KODKodiak Sciences Inc.$31.2M0.18%$1.68$38.54+2194.1%
0.2%
NRIXNurix Therapeutics, Inc.$30.5M0.18%$7.23$23.97+231.5%
0.2%
BMEABiomea Fusion, Inc.$29.0M0.17%$12.71$1.41-88.9%
0.2%
IDYAIDEAYA Biosciences, Inc.$28.7M0.17%$25.83$37.65+45.8%
0.2%
CERSCerus Corporation$27.9M0.16%$1.57$3.16+101.3%
0.2%

Quarter-on-Quarter Activity

Q3 2023 vs. Q2 2023

New Positions (8)

TickerIssuerNotional
IMVTImmunovant, Inc.$16.3M
ARVNArvinas, Inc.$8.1M
TSHATaysha Gene Therapies, Inc.$7.9M
SGMTSagimet Biosciences Inc.$7.2M
Invitae Corporation$6.2M
MIRMMirum Pharmaceuticals, Inc.$6.0M
MORFMorphic Holding, Inc.$4.9M
CELCCelcuity Inc.$4.9M

Exited Positions (8)

TickerIssuerNotional
KDNYChinook Therapeutics, Inc.$55.9M
DICEDICE Therapeutics, Inc.$48.1M
IMGNImmunoGen, Inc.$28.7M
VSTMVerastem, Inc.$9.9M
FATEFate Therapeutics, Inc.$8.0M
ALLOAllogene Therapeutics, Inc.$7.8M
MGNXMacroGenics, Inc.$4.8M
MREOMereo BioPharma Group PLC$4.7M

Increased (8)

TickerIssuerNotionalShares Ξ”Since Filing
CATXXXXXPerspective Therapeutics, Inc.$0.5M+229.4%
DSGNDesign Therapeutics, Inc.$0.4M+200.0%
KALAKALA BIO, Inc.$0.7M+129.4%
EWTXEdgewise Therapeutics, Inc.$2.1M+109.9%
HOOKHOOKIPA Pharma Inc.$1.1M+82.2%
RAREUltragenyx Pharmaceutical Inc.$12.6M+74.5%-3.8%
GLUEMonte Rosa Therapeutics, Inc.$2.8M+62.6%
DNLIDenali Therapeutics Inc.$4.3M+57.5%+30.5%

Trimmed (8)

TickerIssuerNotionalShares Ξ”Since Filing
TLISTalis Biomedical Corporation$-0.7M-93.3%
ANABAnaptysBio, Inc.$-13.9M-86.3%
NVTAQInvitae Corporation$-9.0M-80.1%
RNAMAvidity Biosciences, Inc.$-7.8M-79.2%
PNTPOINT Biopharma Global Inc.$-8.9M-78.6%
SMMTSummit Therapeutics Inc.$-9.9M-50.2%
ARGXargenx SE$-34.8M-46.0%+92.8%
AFMDAffimed N.V.$-1.8M-32.6%
← Back to Hedge Funds